One analyst sees gains of nearly 40% ahead for the biotech's shareholders.
A weaker response to the South African variant prompts studies of a strain-specific booster.
There's a safer way to profit from the cryptocurrency craze.
Will the biotech be large, or will it be huge?
Spoiler alert: The answer could vary somewhat depending on where you live.
The e-commerce platform is starting off the holidays with a bang.
The battle between NVIDIA's and AMD's latest graphics cards could be closer than it appears.
Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.
Just follow these three simple steps.
This story has a long way to go before being over.